Fluidigm, “the South San Francisco-based company, which landed NIH money in a Shark Tank-style program for Covid-19 testing, announced that it will take on an investment worth $250 million from Casdin Capital and Viking Global investors, “. The company “will also rebrand, and call itself Standard BioTools.
